✦ LIBER ✦

PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

✍ Scribed by J Rutkowski; B Gwiosda; B Lisiecka; M Wladysiuk; J Lis; R Plisko; P Rys

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An economic analysis of erlotinib, docet

✍ A. Araújo; B. Parente; R. Sotto-Mayor; E. Teixeira; T. Almodôvar; F. Barata; H. 📂 Article 📅 2008 🏛 Elsevier ⚖ 288 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

Cost-effectiveness analysis of pemetrexe

✍ Yumi Asukai; Amparo Valladares; Carlos Camps; Eifiona Wood; Kaisa Taipale; Jorge 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 781 KB

CN4 COST-EFFECTIVENESS OF PEMETREXED IN

✍ CG Pinto; M Manaças; LS Miguel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

A Retrospective Analysis of Second-Line

✍ Dora Hatzidaki; Sofia Agelaki; Dimitris Mavroudis; Ioannis Vlachonikolis; Athana 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 160 KB

Araújo A, et al. An economic analysis of

✍ Wojciech Bartminski 📂 Article 📅 2009 🏛 Elsevier ⚖ 146 KB